blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1507573

EP1507573 - USE OF DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE IN ADJUVANT THERAPY OF BREAST AND OVARIAN CANCER [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  12.04.2013
Database last updated on 14.09.2024
Most recent event   Tooltip12.04.2013Withdrawal of applicationpublished on 15.05.2013  [2013/20]
Applicant(s)For all designated states
Aventis Pharma S.A.
20, avenue Raymond Aron
92160 Antony / FR
[2005/08]
Inventor(s)01 / CHAKROUN, Hichem
5, Parc Delattre de Tassigny
F-92400 Courbevoie / FR
 [2005/08]
Representative(s)Wright, Robert Gordon McRae
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks
Kent TN13 1XR / GB
[N/P]
Former [2008/52]Wright, Robert Gordon McRae
Elkington and Fife LLP, Prospect House, 8 Pembroke Road Sevenoaks
Kent TN13 1XR / GB
Former [2005/08]Le Pennec, Magali
Aventis Pharma S.A. Direction des Brevets, Tri LEO/144 20, Avenue Raymond Aron
92165 Antony Cedex / FR
Application number, filing date03738122.515.05.2003
[2005/08]
WO2003EP07443
Priority number, dateUS20020380850P17.05.2002         Original published format: US 380850 P
[2005/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03097164
Date:27.11.2003
Language:EN
[2003/48]
Type: A1 Application with search report 
No.:EP1507573
Date:23.02.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 27.11.2003 takes the place of the publication of the European patent application.
[2005/08]
Search report(s)International search report - published on:EP27.11.2003
ClassificationIPC:A61P35/00, A61K31/337, A61K31/351, A61K31/675
[2005/08]
CPC:
A61K31/66 (EP,KR,US); A61K31/337 (EP,KR,US); A61K31/351 (EP,US);
A61K31/675 (EP,US); A61K31/704 (EP,KR,US); A61P15/00 (EP);
A61P35/00 (EP); A61P35/04 (EP) (-)
C-Set:
A61K31/337, A61K2300/00 (EP,US);
A61K31/351, A61K2300/00 (US,EP);
A61K31/66, A61K2300/00 (US,EP);
A61K31/675, A61K2300/00 (EP,US);
A61K31/704, A61K2300/00 (US,EP)
(-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/08]
Extension statesAL17.12.2004
LT17.12.2004
LV17.12.2004
MK17.12.2004
TitleGerman:VERWENDUNG VON DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE IN DER ADJUVANS-THERAPIE VON BRUST- UND OVARIALKREBS[2005/08]
English:USE OF DOCETAXEL/DOXORUBICIN/CYCLOPHOSPHAMIDE IN ADJUVANT THERAPY OF BREAST AND OVARIAN CANCER[2005/08]
French:UTILISATION DE DOCETAXEL/DOXORUBICINE/CYCLOPHOSPHAMIDE DANS LA THERAPIE ADJUVANTE DU CANCER DU SEIN OU DE L'OVAIRE[2005/08]
Entry into regional phase17.12.2004National basic fee paid 
17.12.2004Designation fee(s) paid 
17.12.2004Examination fee paid 
Examination procedure18.11.2003Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.12.2004Examination requested  [2005/08]
26.09.2006Despatch of a communication from the examining division (Time limit: M02)
26.10.2006Reply to a communication from the examining division
18.12.2008Date of oral proceedings
06.03.2009Despatch of communication that the application is refused, reason: substantive examination {1}
06.03.2009Minutes of oral proceedings despatched
05.04.2013Application withdrawn by applicant  [2013/20]
08.04.2013Cancellation of oral proceeding that was planned for 10.04.2013
10.04.2013Date of oral proceedings (cancelled)
Appeal following examination12.05.2009Appeal received No.  T1902/09
16.07.2009Statement of grounds filed
24.07.2012Invitation to file observations in an appeal (Time limit: M02) [2012/30]
05.04.2013Result of appeal procedure: the application was withdrawn
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.09.2006
Fees paidRenewal fee
31.05.2005Renewal fee patent year 03
31.05.2006Renewal fee patent year 04
14.05.2007Renewal fee patent year 05
28.03.2008Renewal fee patent year 06
02.06.2009Renewal fee patent year 07
31.03.2010Renewal fee patent year 08
11.05.2011Renewal fee patent year 09
08.03.2012Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[PX]  - JACKISCH CHRISTIAN ET AL, "Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.", CLINICAL BREAST CANCER. UNITED STATES OCT 2002, (200210), vol. 3, no. 4, ISSN 1526-8209, pages 276 - 280, XP001154935 [PX] 1-11 * abstract *

DOI:   http://dx.doi.org/10.3816/CBC.2002.n.031
 [PX]  - NABHOLTZ JEAN-MARC ET AL, "Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.", JOURNAL OF CLINICAL ONCOLOGY: OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. UNITED STATES 15 MAR 2003, (20030315), vol. 21, no. 6, ISSN 0732-183X, pages 968 - 975, XP009017054 [PX] 1-11 * abstract *

DOI:   http://dx.doi.org/10.1200/JCO.2003.04.040
 [PX]  - SMITH I E, "New drugs for breast cancer", LANCET, XX, XX, (20020907), vol. 360, no. 9335, ISSN 0140-6736, pages 790 - 792, XP004379895 [PX] 1-11 * page 790, column 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/S0140-6736(02)09903-8
 [PX]  - PEREZ E A ET AL, "A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.", ANNALS OF ONCOLOGY: OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO. ENGLAND AUG 2002, (200208), vol. 13, no. 8, ISSN 0923-7534, pages 1225 - 1235, XP009017055 [PX] 1-11 * table 1 *

DOI:   http://dx.doi.org/10.1093/annonc/mdf222
 [PX]  - SMITH ROY E ET AL, "Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.", CLINICAL BREAST CANCER. UNITED STATES DEC 2002, (200212), vol. 3, no. 5, ISSN 1526-8209, pages 333 - 340, XP001155014 [PX] 1-11 * abstract *

DOI:   http://dx.doi.org/10.3816/CBC.2002.n.036
 [PX]  - NABHOLTZ JEAN-MARC ET AL, "Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.", CLINICAL BREAST CANCER. UNITED STATES OCT 2002, (200210), vol. 3, no. 4, ISSN 1526-8209, pages 268 - 275, XP001154933 [PX] 1-11 * abstract *

DOI:   http://dx.doi.org/10.3816/CBC.2002.n.030
 [PX]  - NABHOLTZ JEAN-MARC A ET AL, "Docetaxel in the treatment of breast cancer: An update on recent studies.", SEMINARS IN ONCOLOGY, (200206), vol. 29, no. 3 Suppl. 12, ISSN 0093-7754, pages 28 - 34, XP009017033 [PX] 1-11 * page 31, column 1 *

DOI:   http://dx.doi.org/10.1053/sonc.2002.34262
 [X]  - IKEDA T ET AL, "Neoadjuvant chemotherapy with alternating sequential docetaxel (DOC) and Doxorubicin/Cyclophosphamide (AC) in locally advanced breast cancer (LABC): A pilot study.", EUROPEAN JOURNAL OF CANCER, 2nd European Breast Cancer Conference;Brussels, Belgium; September 26-30, 2000, (200009), vol. 36, no. Supplement 5, ISSN 0959-8049, page S78, XP009017013 [X] 1-11 * abstract *
 [X]  - MAMOUNAS E P, "NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel.", ONCOLOGY (WILLISTON PARK, N.Y.) UNITED STATES JUN 1997, (199706), vol. 11, no. 6 Suppl 6, ISSN 0890-9091, pages 37 - 40, XP009017057 [X] 1-11 * abstract *
 [X]  - "Neoadjuvant docetaxel augments the efficacy of preoperative doxorubicin/cyclophosphamide in operable breast cancer: First results of NSABP B-27", CLINICAL BREAST CANCER 2002 UNITED STATES, (2002), vol. 3, no. 1, ISSN 1526-8209, pages 26 - 28, XP001155019 [X] 1-11 * abstract *
 [X]  - DI LEO A ET AL, "A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.", ANNALS OF ONCOLOGY: OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO. NETHERLANDS FEB 2000, (200002), vol. 11, no. 2, ISSN 0923-7534, pages 169 - 175, XP009017036 [X] 1-11 * abstract *

DOI:   http://dx.doi.org/10.1023/A:1008345432342
 [X]  - D'ORAZIO A I, "Improvement in disease-free survival with doxorubicin/docetaxel/cyclo phosphamide (TAC) versus 5-fluorouracil/doxorubicin/cyclophosphamide (FAC) as adjuvant therapy for node-positive breast cancer", CLINICAL BREAST CANCER 2002 UNITED STATES, (2002), vol. 3, no. 2, ISSN 1526-8209, pages 103 - 105, XP001154934 [X] 1-11 * the whole document *
 [X]  - ANTON A ET AL, "Sequential treatment of docetaxel plus doxorubicin/ cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer (MBC). Final results and survival analysis of a phase II study", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (200203), vol. 38, ISSN 0959-8049, pages S68 - S69, XP004367963 [X] 1-11 * abstract *
 [X]  - NABHOLTZ JEAN-MARC ET AL, "Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.", SEMINARS IN ONCOLOGY, (199810), vol. 25, no. 5 SUPPL. 12, ISSN 0093-7754, pages 27 - 31, XP009017030 [X] 1-11 * abstract *
 [X]  - NABHOLTZ JEAN-MARC ET AL, "Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.", SEMINARS IN ONCOLOGY, (199906), vol. 26, no. 3 SUPPL. 8, ISSN 0093-7754, pages 47 - 52, XP009017031 [X] 1-11 * page 50, column 2 - page 51, column 1 *
 [X]  - NABHOLTZ JEAN-MARC ET AL, "Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From metastatic to adjuvant setting.", SEMINARS IN ONCOLOGY, (199902), vol. 26, no. 1 SUPPL. 3, ISSN 0093-7754, pages 10 - 16, XP009017032 [X] 1-11 * page 15, column 1 *
 [X]  - NABHOLTZ J M ET AL, "Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.", ONCOLOGY (WILLISTON PARK, N.Y.) UNITED STATES AUG 1997, (199708), vol. 11, no. 8 Suppl 8, ISSN 0890-9091, pages 37 - 41, XP009017034 [X] 1-11 * page 51, column 1, paragraph 2 *
by applicantEP0253738
 WO9209589
    - FRANCO CAVELLI ET AL., Textbook of Medical Oncology, MARTIN DUNITZ LTD., (1997), page 4623
    - FUMOLEAU ET AL., BULL. CANCER, (1995), vol. 82, no. 8, pages 629 - 636
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.